At the time of birth, the lungs that had grown the most perhaps functioned the worst. Those kids were born relatively premature, but they didn't respond to surfactant. They had poor compliance of their lungs. It was not a biologically functioning gas exchanging lung.
At the time of birth, the lungs that had grown the most perhaps functioned the worst. Those kids were born relatively premature, but they didn't respond to surfactant. They had poor compliance of their lungs. It was not a biologically functioning gas exchanging lung.
At the time of birth, the lungs that had grown the most perhaps functioned the worst. Those kids were born relatively premature, but they didn't respond to surfactant. They had poor compliance of their lungs. It was not a biologically functioning gas exchanging lung.
most of the time what we do is to wait and treat the neonate still, but we do have a whole armamentarium of options for timing and mode of delivery, and still in a very few cases to with appropriate selection treat patients in utero.
most of the time what we do is to wait and treat the neonate still, but we do have a whole armamentarium of options for timing and mode of delivery, and still in a very few cases to with appropriate selection treat patients in utero.
most of the time what we do is to wait and treat the neonate still, but we do have a whole armamentarium of options for timing and mode of delivery, and still in a very few cases to with appropriate selection treat patients in utero.
Fetoscopic endoluminal tracheal occlusion and twin-twin transfusion: Fetal...
▶Ep 4 · 24:01
quoteOne major difference between Your trial and any trial on uh tracheal occlusion versus the myelomeningocele trial is that you have popularized this over the past 10 years.↗
▶Ep 4 · 24:30
quoteSo, has this impacted your effort to do a trial? Have you been able to recruit the numbers of patients that you anticipated?↗
▶Ep 4 · 40:05
quoteI mean, I would argue, you know, when we did our tracheal occlusion trial, we got tremendous lung growth in some of the kids. We got no lung growth in other kids, and this is with complete tracheal occlusion.↗
▶Ep 4 · 40:24
quoteAt the time of birth, the lungs that had grown the most perhaps functioned the worst. Those kids were born relatively premature, but they didn't respond to surfactant. They had poor compliance of their lungs. It was not a biologically functioning gas exchanging lung.↗
▶Ep 4 · 40:46
quoteI don't think as a rule at this point there's overwhelming data that we improve lung function with tracheal occlusion.↗
quoteyou got to give Mike credit for having, uh, real cojones to, uh, start this field.↗
▶Ep 10 · 0:46
quoteyou got to give Mike credit for having, uh, real cojones to, uh, start this field.↗
▶Ep 10 · 1:08
quotemost of the time what we do is to wait and treat the neonate still, but we do have a whole armamentarium of options for timing and mode of delivery, and still in a very few cases to with appropriate selection treat patients in utero.↗
▶Ep 10 · 1:08
quotemost of the time what we do is to wait and treat the neonate still, but we do have a whole armamentarium of options for timing and mode of delivery, and still in a very few cases to with appropriate selection treat patients in utero.↗
▶Ep 10 · 3:45
clinicalBronchial atresia can be differentiated from microcystic CPAM by the presence of a dilated central bronchus or mucocele and documentation of a contralateral lung to rule out lung agenesis.↗
▶Ep 10 · 3:45
clinicalBronchial atresia can be differentiated from microcystic CPAM by the presence of a dilated central bronchus or mucocele and documentation of a contralateral lung to rule out lung agenesis.↗
▶Ep 10 · 6:11
clinicalCVR >1.6 predicts high risk for CPAM evolving into hydrops, particularly for microcystic lesions.↗
▶Ep 10 · 6:11
clinicalCVR >1.6 predicts high risk for CPAM evolving into hydrops, particularly for microcystic lesions.↗
▶Ep 10 · 6:23
clinicalMaternal steroids are first-line therapy for high-risk CPAM (CVR >1.6); the majority respond, but open fetal surgery is considered if hydrops persists despite steroids at an early gestational age.↗
▶Ep 10 · 6:23
clinicalMaternal steroids are first-line therapy for high-risk CPAM (CVR >1.6); the majority respond, but open fetal surgery is considered if hydrops persists despite steroids at an early gestational age.↗
▶Ep 10 · 6:31
clinicalOpen fetal surgery for CPAM is indicated when hydrops persists despite steroids at an early gestational time point, if the capability exists.↗
▶Ep 10 · 6:31
clinicalOpen fetal surgery for CPAM is indicated when hydrops persists despite steroids at an early gestational time point, if the capability exists.↗
▶Ep 10 · 9:08
quoteThe key to fetal surgery is putting the kid back in the uterus and keeping them there for an adequate length of time for lung growth to occur.↗
▶Ep 10 · 9:08
quoteThe key to fetal surgery is putting the kid back in the uterus and keeping them there for an adequate length of time for lung growth to occur.↗
▶Ep 10 · 9:40
clinicalMacrocystic CPAM can be treated by thoracoamniotic shunt rather than open fetal surgery.↗
▶Ep 10 · 9:40
clinicalMacrocystic CPAM can be treated by thoracoamniotic shunt rather than open fetal surgery.↗
▶Ep 10 · 10:34
epidemiologicalCHOP's open fetal surgery for CPAM has approximately 60% survival; thoracoamniotic shunts have 70-75% survival.↗
▶Ep 10 · 10:34
epidemiologicalCHOP's open fetal surgery for CPAM has approximately 60% survival; thoracoamniotic shunts have 70-75% survival.↗
▶Ep 10 · 10:49
clinicalBronchial atresia is more difficult to treat by fetal intervention than CPAM; CHOP has had one intraoperative fetal death, one postnatal hepatic necrosis death, and one likely survivor out of three cases.↗
▶Ep 10 · 10:49
clinicalBronchial atresia is more difficult to treat by fetal intervention than CPAM; CHOP has had one intraoperative fetal death, one postnatal hepatic necrosis death, and one likely survivor out of three cases.↗
▶Ep 10 · 12:18
clinicalSacrococcygeal teratoma fetal intervention targets tumor vascular steal leading to high-output cardiac failure; surgical debulking interrupts the arteriovenous steal.↗
▶Ep 10 · 12:18
clinicalSacrococcygeal teratoma fetal intervention targets tumor vascular steal leading to high-output cardiac failure; surgical debulking interrupts the arteriovenous steal.↗
▶Ep 10 · 16:03
clinicalWatchful waiting for SCT between 27-32 weeks can be hazardous; the majority of patients who go into preterm labor or evolve significant high-output failure will die.↗
▶Ep 10 · 16:03
clinicalWatchful waiting for SCT between 27-32 weeks can be hazardous; the majority of patients who go into preterm labor or evolve significant high-output failure will die.↗
▶Ep 10 · 16:33
clinicalCHOP's recent SCT algorithm emphasizes preemptive early delivery (≥27 weeks) at the first sign of maternal or fetal decompensation, with improved outcomes in 5 recent cases.↗
▶Ep 10 · 16:33
clinicalCHOP's recent SCT algorithm emphasizes preemptive early delivery (≥27 weeks) at the first sign of maternal or fetal decompensation, with improved outcomes in 5 recent cases.↗
▶Ep 10 · 17:33
clinicalRFA (radiofrequency ablation) technology for SCT has not identified a safe ablative technology that avoids collateral injury and bad outcomes; it is not recommended at present.↗
▶Ep 10 · 17:33
clinicalRFA (radiofrequency ablation) technology for SCT has not identified a safe ablative technology that avoids collateral injury and bad outcomes; it is not recommended at present.↗
▶Ep 10 · 18:25
clinicalThe EXIT procedure was initially developed to remove tracheal clips after tracheal occlusion for CDH.↗
▶Ep 10 · 18:25
clinicalThe EXIT procedure was initially developed to remove tracheal clips after tracheal occlusion for CDH.↗
▶Ep 10 · 18:41
clinicalThe EXIT procedure maintains uteroplacental blood flow using complete uterine relaxation with deep maternal gaseous anesthetic and intrauterine volume maintenance.↗
▶Ep 10 · 18:41
clinicalThe EXIT procedure maintains uteroplacental blood flow using complete uterine relaxation with deep maternal gaseous anesthetic and intrauterine volume maintenance.↗
▶Ep 10 · 19:10
clinicalThe EXIT procedure requires a multidisciplinary team with specific roles, and may require a second operating room team for definitive postnatal procedures and ECMO capability.↗
▶Ep 10 · 19:10
clinicalThe EXIT procedure requires a multidisciplinary team with specific roles, and may require a second operating room team for definitive postnatal procedures and ECMO capability.↗
▶Ep 10 · 20:04
clinicalA massive cervical teratoma case required 11.5 hours on placental support during EXIT, with retrograde and antegrade cannulation attempts, ultimately requiring tumor dissection to reach the trachea.↗
▶Ep 10 · 20:04
clinicalA massive cervical teratoma case required 11.5 hours on placental support during EXIT, with retrograde and antegrade cannulation attempts, ultimately requiring tumor dissection to reach the trachea.↗
▶Ep 10 · 21:05
clinicalCHAOS (congenital high airway obstruction syndrome) can result in marked diaphragm inversion, ascites, and thoracic abnormalities; the first survivor was delivered by EXIT.↗
▶Ep 10 · 21:05
clinicalCHAOS (congenital high airway obstruction syndrome) can result in marked diaphragm inversion, ascites, and thoracic abnormalities; the first survivor was delivered by EXIT.↗
▶Ep 10 · 21:33
opinionCHAOS has a strong rationale for prenatal treatment due to morbidity associated with treating at birth and the need for patients to grow into their ventilatory mechanics.↗
▶Ep 10 · 21:33
opinionCHAOS has a strong rationale for prenatal treatment due to morbidity associated with treating at birth and the need for patients to grow into their ventilatory mechanics.↗
▶Ep 10 · 23:57
opinionFuture directions in fetal surgery include clinical trials, reduction of maternal and fetal risk, better imaging for physiologic information, and tissue engineering approaches to make open fetal surgery obsolete.↗
▶Ep 10 · 23:57
opinionFuture directions in fetal surgery include clinical trials, reduction of maternal and fetal risk, better imaging for physiologic information, and tissue engineering approaches to make open fetal surgery obsolete.↗
▶Ep 10 · 26:38
clinicalThe CPAM volume ratio (CVR) is calculated by measuring the CPAM in 3 dimensions, applying an ellipse formula, and dividing by head circumference to standardize for gestational age.↗
▶Ep 10 · 26:38
clinicalThe CPAM volume ratio (CVR) is calculated by measuring the CPAM in 3 dimensions, applying an ellipse formula, and dividing by head circumference to standardize for gestational age.↗
▶Ep 10 · 29:19
clinicalMacrocystic CPAM and bronchial atresia do not respond as well to steroids as microcystic CPAM.↗
▶Ep 10 · 29:19
clinicalMacrocystic CPAM and bronchial atresia do not respond as well to steroids as microcystic CPAM.↗
quoteyou got to give Mike credit for having, uh, real cojones to, uh, start this field.↗
▶Ep 8 · 1:08
quotemost of the time what we do is to wait and treat the neonate still, but we do have a whole armamentarium of options for timing and mode of delivery, and still in a very few cases to with appropriate selection treat patients in utero.↗
▶Ep 8 · 3:45
clinicalBronchial atresia can be differentiated from microcystic CPAM by the presence of a dilated central bronchus or mucocele and documentation of a contralateral lung to rule out lung agenesis.↗
▶Ep 8 · 6:11
clinicalCVR >1.6 predicts high risk for CPAM evolving into hydrops, particularly for microcystic lesions.↗
▶Ep 8 · 6:23
clinicalMaternal steroids are first-line therapy for high-risk CPAM (CVR >1.6); the majority respond, but open fetal surgery is considered if hydrops persists despite steroids at an early gestational age.↗
▶Ep 8 · 6:31
clinicalOpen fetal surgery for CPAM is indicated when hydrops persists despite steroids at an early gestational time point, if the capability exists.↗
▶Ep 8 · 9:08
quoteThe key to fetal surgery is putting the kid back in the uterus and keeping them there for an adequate length of time for lung growth to occur.↗
▶Ep 8 · 9:40
clinicalMacrocystic CPAM can be treated by thoracoamniotic shunt rather than open fetal surgery.↗
▶Ep 8 · 10:34
epidemiologicalCHOP's open fetal surgery for CPAM has approximately 60% survival; thoracoamniotic shunts have 70-75% survival.↗
▶Ep 8 · 10:49
clinicalBronchial atresia is more difficult to treat by fetal intervention than CPAM; CHOP has had one intraoperative fetal death, one postnatal hepatic necrosis death, and one likely survivor out of three cases.↗
▶Ep 8 · 12:18
clinicalSacrococcygeal teratoma fetal intervention targets tumor vascular steal leading to high-output cardiac failure; surgical debulking interrupts the arteriovenous steal.↗
▶Ep 8 · 16:03
clinicalWatchful waiting for SCT between 27-32 weeks can be hazardous; the majority of patients who go into preterm labor or evolve significant high-output failure will die.↗
▶Ep 8 · 16:33
clinicalCHOP's recent SCT algorithm emphasizes preemptive early delivery (≥27 weeks) at the first sign of maternal or fetal decompensation, with improved outcomes in 5 recent cases.↗
▶Ep 8 · 17:33
clinicalRFA (radiofrequency ablation) technology for SCT has not identified a safe ablative technology that avoids collateral injury and bad outcomes; it is not recommended at present.↗
▶Ep 8 · 18:25
clinicalThe EXIT procedure was initially developed to remove tracheal clips after tracheal occlusion for CDH.↗
▶Ep 8 · 18:41
clinicalThe EXIT procedure maintains uteroplacental blood flow using complete uterine relaxation with deep maternal gaseous anesthetic and intrauterine volume maintenance.↗
▶Ep 8 · 19:10
clinicalThe EXIT procedure requires a multidisciplinary team with specific roles, and may require a second operating room team for definitive postnatal procedures and ECMO capability.↗
▶Ep 8 · 20:04
clinicalA massive cervical teratoma case required 11.5 hours on placental support during EXIT, with retrograde and antegrade cannulation attempts, ultimately requiring tumor dissection to reach the trachea.↗
▶Ep 8 · 21:05
clinicalCHAOS (congenital high airway obstruction syndrome) can result in marked diaphragm inversion, ascites, and thoracic abnormalities; the first survivor was delivered by EXIT.↗
▶Ep 8 · 21:33
opinionCHAOS has a strong rationale for prenatal treatment due to morbidity associated with treating at birth and the need for patients to grow into their ventilatory mechanics.↗
▶Ep 8 · 23:57
opinionFuture directions in fetal surgery include clinical trials, reduction of maternal and fetal risk, better imaging for physiologic information, and tissue engineering approaches to make open fetal surgery obsolete.↗
▶Ep 8 · 26:38
clinicalThe CPAM volume ratio (CVR) is calculated by measuring the CPAM in 3 dimensions, applying an ellipse formula, and dividing by head circumference to standardize for gestational age.↗
▶Ep 8 · 29:19
clinicalMacrocystic CPAM and bronchial atresia do not respond as well to steroids as microcystic CPAM.↗
quoteyou got to give Mike credit for having, uh, real cojones to, uh, start this field.↗
▶Ep 9 · 0:46
quoteyou got to give Mike credit for having, uh, real cojones to, uh, start this field.↗
▶Ep 9 · 1:08
quotemost of the time what we do is to wait and treat the neonate still, but we do have a whole armamentarium of options for timing and mode of delivery, and still in a very few cases to with appropriate selection treat patients in utero.↗
▶Ep 9 · 1:08
quotemost of the time what we do is to wait and treat the neonate still, but we do have a whole armamentarium of options for timing and mode of delivery, and still in a very few cases to with appropriate selection treat patients in utero.↗
▶Ep 9 · 3:45
clinicalBronchial atresia can be differentiated from microcystic CPAM by the presence of a dilated central bronchus or mucocele and documentation of a contralateral lung to rule out lung agenesis.↗
▶Ep 9 · 3:45
clinicalBronchial atresia can be differentiated from microcystic CPAM by the presence of a dilated central bronchus or mucocele and documentation of a contralateral lung to rule out lung agenesis.↗
▶Ep 9 · 6:11
clinicalCVR >1.6 predicts high risk for CPAM evolving into hydrops, particularly for microcystic lesions.↗
▶Ep 9 · 6:11
clinicalCVR >1.6 predicts high risk for CPAM evolving into hydrops, particularly for microcystic lesions.↗
▶Ep 9 · 6:23
clinicalMaternal steroids are first-line therapy for high-risk CPAM (CVR >1.6); the majority respond, but open fetal surgery is considered if hydrops persists despite steroids at an early gestational age.↗
▶Ep 9 · 6:23
clinicalMaternal steroids are first-line therapy for high-risk CPAM (CVR >1.6); the majority respond, but open fetal surgery is considered if hydrops persists despite steroids at an early gestational age.↗
▶Ep 9 · 6:31
clinicalOpen fetal surgery for CPAM is indicated when hydrops persists despite steroids at an early gestational time point, if the capability exists.↗
▶Ep 9 · 6:31
clinicalOpen fetal surgery for CPAM is indicated when hydrops persists despite steroids at an early gestational time point, if the capability exists.↗
▶Ep 9 · 9:08
quoteThe key to fetal surgery is putting the kid back in the uterus and keeping them there for an adequate length of time for lung growth to occur.↗
▶Ep 9 · 9:08
quoteThe key to fetal surgery is putting the kid back in the uterus and keeping them there for an adequate length of time for lung growth to occur.↗
▶Ep 9 · 9:40
clinicalMacrocystic CPAM can be treated by thoracoamniotic shunt rather than open fetal surgery.↗
▶Ep 9 · 9:40
clinicalMacrocystic CPAM can be treated by thoracoamniotic shunt rather than open fetal surgery.↗
▶Ep 9 · 10:34
epidemiologicalCHOP's open fetal surgery for CPAM has approximately 60% survival; thoracoamniotic shunts have 70-75% survival.↗
▶Ep 9 · 10:34
epidemiologicalCHOP's open fetal surgery for CPAM has approximately 60% survival; thoracoamniotic shunts have 70-75% survival.↗
▶Ep 9 · 10:49
clinicalBronchial atresia is more difficult to treat by fetal intervention than CPAM; CHOP has had one intraoperative fetal death, one postnatal hepatic necrosis death, and one likely survivor out of three cases.↗
▶Ep 9 · 10:49
clinicalBronchial atresia is more difficult to treat by fetal intervention than CPAM; CHOP has had one intraoperative fetal death, one postnatal hepatic necrosis death, and one likely survivor out of three cases.↗
▶Ep 9 · 12:18
clinicalSacrococcygeal teratoma fetal intervention targets tumor vascular steal leading to high-output cardiac failure; surgical debulking interrupts the arteriovenous steal.↗
▶Ep 9 · 12:18
clinicalSacrococcygeal teratoma fetal intervention targets tumor vascular steal leading to high-output cardiac failure; surgical debulking interrupts the arteriovenous steal.↗
▶Ep 9 · 16:03
clinicalWatchful waiting for SCT between 27-32 weeks can be hazardous; the majority of patients who go into preterm labor or evolve significant high-output failure will die.↗
▶Ep 9 · 16:03
clinicalWatchful waiting for SCT between 27-32 weeks can be hazardous; the majority of patients who go into preterm labor or evolve significant high-output failure will die.↗
▶Ep 9 · 16:33
clinicalCHOP's recent SCT algorithm emphasizes preemptive early delivery (≥27 weeks) at the first sign of maternal or fetal decompensation, with improved outcomes in 5 recent cases.↗
▶Ep 9 · 16:33
clinicalCHOP's recent SCT algorithm emphasizes preemptive early delivery (≥27 weeks) at the first sign of maternal or fetal decompensation, with improved outcomes in 5 recent cases.↗
▶Ep 9 · 17:33
clinicalRFA (radiofrequency ablation) technology for SCT has not identified a safe ablative technology that avoids collateral injury and bad outcomes; it is not recommended at present.↗
▶Ep 9 · 17:33
clinicalRFA (radiofrequency ablation) technology for SCT has not identified a safe ablative technology that avoids collateral injury and bad outcomes; it is not recommended at present.↗
▶Ep 9 · 18:25
clinicalThe EXIT procedure was initially developed to remove tracheal clips after tracheal occlusion for CDH.↗
▶Ep 9 · 18:25
clinicalThe EXIT procedure was initially developed to remove tracheal clips after tracheal occlusion for CDH.↗
▶Ep 9 · 18:41
clinicalThe EXIT procedure maintains uteroplacental blood flow using complete uterine relaxation with deep maternal gaseous anesthetic and intrauterine volume maintenance.↗
▶Ep 9 · 18:41
clinicalThe EXIT procedure maintains uteroplacental blood flow using complete uterine relaxation with deep maternal gaseous anesthetic and intrauterine volume maintenance.↗
▶Ep 9 · 19:10
clinicalThe EXIT procedure requires a multidisciplinary team with specific roles, and may require a second operating room team for definitive postnatal procedures and ECMO capability.↗
▶Ep 9 · 19:10
clinicalThe EXIT procedure requires a multidisciplinary team with specific roles, and may require a second operating room team for definitive postnatal procedures and ECMO capability.↗
▶Ep 9 · 20:04
clinicalA massive cervical teratoma case required 11.5 hours on placental support during EXIT, with retrograde and antegrade cannulation attempts, ultimately requiring tumor dissection to reach the trachea.↗
▶Ep 9 · 20:04
clinicalA massive cervical teratoma case required 11.5 hours on placental support during EXIT, with retrograde and antegrade cannulation attempts, ultimately requiring tumor dissection to reach the trachea.↗
▶Ep 9 · 21:05
clinicalCHAOS (congenital high airway obstruction syndrome) can result in marked diaphragm inversion, ascites, and thoracic abnormalities; the first survivor was delivered by EXIT.↗
▶Ep 9 · 21:05
clinicalCHAOS (congenital high airway obstruction syndrome) can result in marked diaphragm inversion, ascites, and thoracic abnormalities; the first survivor was delivered by EXIT.↗
▶Ep 9 · 21:33
opinionCHAOS has a strong rationale for prenatal treatment due to morbidity associated with treating at birth and the need for patients to grow into their ventilatory mechanics.↗
▶Ep 9 · 21:33
opinionCHAOS has a strong rationale for prenatal treatment due to morbidity associated with treating at birth and the need for patients to grow into their ventilatory mechanics.↗
▶Ep 9 · 23:57
opinionFuture directions in fetal surgery include clinical trials, reduction of maternal and fetal risk, better imaging for physiologic information, and tissue engineering approaches to make open fetal surgery obsolete.↗
▶Ep 9 · 23:57
opinionFuture directions in fetal surgery include clinical trials, reduction of maternal and fetal risk, better imaging for physiologic information, and tissue engineering approaches to make open fetal surgery obsolete.↗
▶Ep 9 · 26:38
clinicalThe CPAM volume ratio (CVR) is calculated by measuring the CPAM in 3 dimensions, applying an ellipse formula, and dividing by head circumference to standardize for gestational age.↗
▶Ep 9 · 26:38
clinicalThe CPAM volume ratio (CVR) is calculated by measuring the CPAM in 3 dimensions, applying an ellipse formula, and dividing by head circumference to standardize for gestational age.↗
▶Ep 9 · 29:19
clinicalMacrocystic CPAM and bronchial atresia do not respond as well to steroids as microcystic CPAM.↗
▶Ep 9 · 29:19
clinicalMacrocystic CPAM and bronchial atresia do not respond as well to steroids as microcystic CPAM.↗
Fetoscopic endoluminal tracheal occlusion and twin-twin transfusion: Fetal...
▶Ep 10 · 24:01
quoteOne major difference between Your trial and any trial on uh tracheal occlusion versus the myelomeningocele trial is that you have popularized this over the past 10 years.↗
▶Ep 10 · 24:30
quoteSo, has this impacted your effort to do a trial? Have you been able to recruit the numbers of patients that you anticipated?↗
▶Ep 10 · 40:05
quoteI mean, I would argue, you know, when we did our tracheal occlusion trial, we got tremendous lung growth in some of the kids. We got no lung growth in other kids, and this is with complete tracheal occlusion.↗
▶Ep 10 · 40:24
quoteAt the time of birth, the lungs that had grown the most perhaps functioned the worst. Those kids were born relatively premature, but they didn't respond to surfactant. They had poor compliance of their lungs. It was not a biologically functioning gas exchanging lung.↗
▶Ep 10 · 40:46
quoteI don't think as a rule at this point there's overwhelming data that we improve lung function with tracheal occlusion.↗
Fetoscopic endoluminal tracheal occlusion and twin-twin transfusion: Fetal...
▶Ep 4 · 24:01
quoteOne major difference between Your trial and any trial on uh tracheal occlusion versus the myelomeningocele trial is that you have popularized this over the past 10 years.↗
▶Ep 4 · 24:30
quoteSo, has this impacted your effort to do a trial? Have you been able to recruit the numbers of patients that you anticipated?↗
▶Ep 4 · 40:05
quoteI mean, I would argue, you know, when we did our tracheal occlusion trial, we got tremendous lung growth in some of the kids. We got no lung growth in other kids, and this is with complete tracheal occlusion.↗
▶Ep 4 · 40:24
quoteAt the time of birth, the lungs that had grown the most perhaps functioned the worst. Those kids were born relatively premature, but they didn't respond to surfactant. They had poor compliance of their lungs. It was not a biologically functioning gas exchanging lung.↗
▶Ep 4 · 40:46
quoteI don't think as a rule at this point there's overwhelming data that we improve lung function with tracheal occlusion.↗
